ALTERNATIVE CANCER SOLUTION |
|||
|---|---|---|---|
| Home | About Us | FAQ | Cancer Therapy | Contact us | Telephone Consultations | Supplements | |||
|
Cancer Treatment and Alternative Therapy. Subsequent to Pauling’s studies, two randomized placebo-controlled studies conducted at the Mayo clinic found no differences in outcome between terminal cancer patients receiving 10 grams per day orally or placebo. The obvious difference between the Mayo clinic studies and the Pauling studies, was that The Mayo clinic did not use intravenous vitamin C. In the 1990s, Hugh Riordan, MD and colleagues demonstrated that most tumor cell types, when exposed to a vitamin C concentration of 400 mg/dl in a culture medium, quickly die, while normal cells remain unaffected. Concentrations such as listed above can only be achieved through intravenous administration. In August of 2005, Mark Levine, MD and colleagues, from the National Institutes of Health, performed a study similar to that of Hugh Riordan. They took several different cancer cell lines as well as normal cells, and exposed them to vitamin C in a culture medium. Using vitamin C concentrations only achievable through intravenous administration, Dr. Levine found that 5 different cancer cell lines died, while normal cells were unaffected. The mechanism of death to cancer cells was high levels of intracellular hydrogen peroxide which were produced in response to the vitamin C. Since the 1970s, many cancer patients have been treated with regular infusions of high dose intravenous vitamin C. Some patients have been reported to be cured, while some went on to live many years with their cancer. Unfortunately, there are no large randomized, placebo-controlled, double blind studies with IV vitamin C, as are done with all new FDA approved drugs. Most studies such as these are funded by large pharmaceutical companies. Vitamin C simply has not grabbed the attention of the pharmaceutical industry, because a patent cannot be obtained on vitamins. There is little money to be made from large investments in vitamin research. Many of us are hopeful, however, that the study performed by Dr. Levine with the NIH will inspire a new avenue of research.
Protocol for Vitamin C and other antioxidants at the Institute for Healthy Aging At the Institute, our intravenous infusions consist of not only vitamin C, but also other antioxidants such as intravenous vitamin E, glutathione, and alpha lipoic acid. These antioxidants work synergistically and increase the effectiveness of vitamin C. Oral supplementation, especially between infusion days, has been found to be a very helpful adjunct to the intravenous infusions. The list of oral supplements can be significant and play an important role in successful cancer treatment. Many Oncologists Recommend Avoiding Antioxidants during Chemotherapy or Radiation Therapy – Is there Validity to this Concern? Well documented cases of advanced cancers responding to intravenous vitamin C therapy Early clinical studies showed that high-dose vitamin C, given by intravenous and oral routes, may improve symptoms and prolong life in patients with terminal cancer. Double-blind placebo-controlled studies of oral vitamin C therapy showed no benefit. Recent evidence shows that oral administration of the maximum tolerated dose of vitamin C (18 g/d) produces peak plasma concentrations of only 220 µmol/L, whereas intravenous administration of the same dose produces plasma concentrations about 25-fold higher. Larger doses (50–100 g) given intravenously may result in plasma concentrations of about 14 000 µmol/L. At concentrations above 1000 µmol/L, vitamin C is toxic to some cancer cells but not to normal cells in vitro. We found 3 well-documented cases of advanced cancers, confirmed by histopathologic review, where patients had unexpectedly long survival times after receiving high-dose intravenous vitamin C therapy. We examined clinical details of each case in accordance with National Cancer Institute (NCI) Best Case Series guidelines. Tumour pathology was verified by pathologists at the NCI who were unaware of diagnosis or treatment. In light of recent clinical pharmacokinetic findings and in vitro evidence of anti-tumour mechanisms, these case reports indicate that the role of high-dose intravenous vitamin C therapy in cancer treatment should be reassessed. Thirty years ago Cameron, Campbell and Pauling reported beneficial effects of high-dose vitamin C (ascorbic acid) therapy for patients with terminal cancer.1–4 Subsequent double-blind, randomized clinical trials at the Mayo Clinic failed to show any benefit,5,6 and the role of vitamin C in cancer treatment was discarded by mainstream oncologists.7,8 Vitamin C continues, however, to be used as an alternative cancer therapy9,10 New information is available pertaining to biological plausibility. Although similar doses of vitamin C were used in the Cameron–Pauling and Mayo Clinic studies, the Cameron–Pauling studies combined intravenous and oral administration whereas the Mayo Clinic studies used only oral administration.1,2,12–14 Recent pharmacokinetics modeling15indicates that with oral administration, even very large and frequent doses of vitamin C will increase plasma concentrations only modestly, from 70 µmol/L to a maximum of 220 µmol/L, whereas intravenous administration raises plasma concentrations as high as 14 000 µmol/L. Concentrations of 1000–5000 µmol/L are selectively cytotoxic to tumour cells in vitro,16–20and emerging evidence indicates that ascorbic acid at concentrations achieved only by the intravenous route may function as a pro-drug for hydrogen peroxide delivery to tissues.20 The in vitro biologic evidence and clinical pharmacokinetics data confer biological plausibility to the notion that vitamin C could affect cancer biology and may explain in part the negative results of the Mayo Clinic trials.13,15,21,22 Thus, sufficient evidence has accumulated, not to use vitamin C as cancer treatment, but to further explore the therapeutic concept. One way to increase the clinical plausibility of alternative cancer therapies is rigorous, well-documented case reporting, as laid out in the US National Cancer Institute (NCI) Best Case Series guidelines (http://www3.cancer.gov/occam/bestcase.html).23,24 Such case series might identify alternative therapies that merit further investigation.23,24. Case reports of apparent responses by malignant disease to intravenous vitamin C therapy have appeared,25–30 including those of 2 of the 3 patients presented below.25,26 However, they were reported without sufficient detail or with incomplete follow-up for evaluation and without conforming to NCI Best Case Series guidelines. They also lacked objective pathologic confirmation, which is a pillar of NCI guidelines. In this article, we use NCI Best Case Series guidelines to report 3 cases of patients with usually progressive malignant disease who received intravenous vitamin C therapy as their only significant cancer therapy and whose clinical courses were unusually favourable. Original diagnostic material obtained before treatment with vitamin C was reviewed by pathologists at the National Institutes of Health (NIH) who were unaware of the diagnoses and treatments4.
Intravenous Vitamin D2 Analogue
In addition, treating prostate cancer cells with paricalcitol made these cells more susceptible to the destructive effects of radiation therapy, without harming normal cells. Because paricalcitol has very little calcemic activity, it can be given at higher doses than vitamin D3 without toxicity, potentially leading to greater efficacy in the treatment of vitamin D3-sensitive cancers. Research has shown that paricalcitol may be affective for many types of solid tumors; Roswell Park Cancer Institute is currently recruiting patients for enrollment in a clinical trial treating various solid tumors, as well as multiple myeloma with paricalcitol. Hormonal Therapy LHRH/Gonadotropin Releasing Hormone Agonists (GnRH agonists)
Matrix metalloproteinase inhibitor
Carbogen and Vasodilation Therapy One of the biggest, if not the primary obstacle to treating cancer is the fact that tumor blood flow is extremely poor. Intravenous chemotherapy will obviously be ineffective if the blood is not sufficiently perfusing the tumor. In addition, radiation therapy requires a well oxygenated tumor to have optimal destruction of tumor cells. Studies also reveal that poorly oxygenated tumors are more prone to metastasize, and are more prone to undergo angiogenesis (develop new blood vessels to feed itself). Several studies have also shown a positive correlation with the grade of the tumor and the oxygen status (the lower the partial pressure of oxygen in the tumor, the higher the grade off cancer). In addition, certain drugs that cause tumor vessels to dilate have revealed improved tumor blood flow, and thereby increased responsiveness to treatment. One of the best dilators of tumor vessels is isosorbide dinitrate, a commonly used drug to treat angina. At the Institute, we incorporate the use of both carbogen breathing and isosorbide dinitrate, while administering intravenous antioxidant therapy.
Biography Contact |
|||
Home | About Us | FAQ | Cancer Therapy | Contact us | Telephone Consultations | Supplements
|